Axsome Therapeutics Inc (AXSM) financials
Axsome Therapeutics revenue and earnings by year
Axsome Therapeutics's revenue was $638 million in the fiscal year to December 31, 2025, up 65.5% from the year before. Net income was -$183 million, -28.7% of revenue. Since the fiscal year to December 31, 2022, revenue has grown 133.6% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 4 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 638 | 386 | 271 | 50 |
| Revenue growth | 65.5% | 42.5% | 440.8% | — |
| Gross profit | 591 | 352 | 245 | 45 |
| Gross margin | 92.6% | 91.4% | 90.4% | 89.6% |
| Operating income | -167 | -281 | -232 | -180 |
| Operating margin | -26.1% | -72.7% | -85.7% | -359.3% |
| Net income | -183 | -287 | -239 | -187 |
| Net margin | -28.7% | -74.5% | -88.4% | -374.0% |
| Diluted EPS | -$3.68 | -$5.99 | -$5.27 | -$4.60 |
| Free cash flow | -94 | -129 | -146 | -117 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open AXSM in Markets.
How Axsome Therapeutics makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Product | $216M | 99.1% |
| Royalty & Milestone Revenue | $2.02M | 0.9% |
See also: AXSM returns
No forecast, no recommendation. This page describes Axsome Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.